SCHEMBL5491548

SCHEMBL5491548

C1=NC=NC2CC3CCCNC3=CC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11063545 1.00
SCHEMBL9777662 0.76
SCHEMBL10745821 0.71
SCHEMBL7106992 0.71
SCHEMBL9823953 0.70
SCHEMBL9823784 0.70
SCHEMBL11037243 0.69
SCHEMBL10763563 0.67
SCHEMBL7292397 0.67
SCHEMBL191190 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4501890-A ANTIDEPRESSANTS, HYPOTENSIVE AND ANTISECRETORY AGENTS, PROLACTIN INHIBITOR AND TREATMENT OF PARKINSONS DISEASE ELI LILLY AND COMPANY (US) 1985-02-26 US claimed
US-7226910-B2 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists VIVUS, INC. (US) 2007-06-05 US disclosed
WO-2006127057-A1 NON-SYSTEMATIC VAGINAL ADMINISTRATION OF ESTROGEN AND AN ANDROGEN FOR THE TREATMENT OF SEXUAL DYSFUNCTION LYLE CORPORATE DRVELOPMENT, INC. (US) 2006-11-30 WO disclosed
EP-1418920-A4 AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS VIVUS INC (US) 2006-10-04 EP disclosed
EP-1420795-A4 AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS VIVUS INC (US) 2006-09-06 EP disclosed
US-20060041021-A1 Treatment of female sexual dysfunction with vasoactive intestinal polypeptide agonists VIVUS, INC. (US) 2006-02-23 US disclosed
US-20050070516-A1 As-needed administration of an androgenic agent to enhance female desire and responsiveness VIVUS INC. (US) 2005-03-31 US disclosed
EP-1420795-A1 AS-NEEDED ADMINISTRATION OF AN ANDROGENIC AGENT TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS Vivus, Inc. (US) 2004-05-26 EP disclosed
EP-1418920-A1 AS-NEEDED ADMINISTRATION OF ORALLY ACTIVE ANDROGENIC AGENTS TO ENHANCE FEMALE SEXUAL DESIRE AND RESPONSIVENESS Vivus, Inc. (US) 2004-05-19 EP disclosed
US-20030207852-A1 Treatment of female sexual dysfunction PLACE VIRGIL A (US) 2003-11-06 US disclosed
US-6306841-B1 NITROVASODILATOR SELECTED FROM SODIUM NITROPRUSSIDE, DIAZENIUM DIOLATE MOLSIDOMINE, LINSIDOMINE CHLORHYDRATE, S-NITROSOTHIOLS, ORGANIC NITRATES, PHARMACOLOGICALLY ACCEPTABLE SALTS, ASIVI, LLC 2001-10-23 US disclosed
US-6294550-B1 ADMINISTERING A VASOACTIVE AGENT FROM ERGOTAMINE DRUG ASIVI, LLC 2001-09-25 US disclosed
EP-1027057-A1 TREATMENT OF FEMALE SEXUAL DYSFUNCTION Asivi, LLC (US) 2000-08-16 EP disclosed
WO-1999021562-A1 TREATMENT OF FEMALE SEXUAL DYSFUNCTION ASIVI, LLC (US) 1999-05-06 WO disclosed
EP-0138417-B1 2-SUBSTITUTED PYRIMIDOHEXAHYDROQUINOLINES ELI LILLY AND COMPANY (US) 1990-03-14 EP disclosed
EP-0171277-A2 Improvements in or relating to tricycling quinoline derivatives ELI LILLY AND COMPANY (US) 1986-02-12 EP disclosed
US-4537964-A Method of preparing permissibly-substituted 1H(and 2H)pyrazolo[3,4-g]quinolines; pyrimido[4,5,g]quinolines; thiazolo[4,5,g]quinolines and intermediates therefore ELI LILLY AND COMPANY (US) 1985-08-27 US disclosed
US-4537964-A Method of preparing permissibly-substituted 1H(and 2H)pyrazolo[3,4-g]quinolines; pyrimido[4,5,g]quinolines; thiazolo[4,5,g]quinolines and intermediates therefore ELI LILLY AND COMPANY (US) 1985-08-27 US disclosed
US-4521421-A USING 2-AMINO-OCTAHYDROPYRIMIDO(4,5-G)QUINOLINE COMPOUND ELI LILLY AND COMPANY (US) 1985-06-04 US disclosed
EP-0142920-A2 6-Oxodecahydroquinolines and process for their preparation ELI LILLY AND COMPANY (US) 1985-05-29 EP disclosed